Admetsys
Admetsys develops a clinical robotics system for critical care and surgery that automates blood analysis and metabolic control. Their flagship product, PrecisionOne™, uses AI to model patient metabolism in real time and autonomously regulate glucose by infusing insulin and dextrose therapy without clinician intervention. The Intravenous Laboratory™ provides continuous, real-time blood diagnostics with a cartridge-based design measuring multiple analytes including glucose and lactate, enabling early sepsis detection and improved glucose control. The system improves clinical outcomes by reducing mortality, shortening ICU stays, and lowering costs. It addresses critical care challenges such as frequent blood draws and nursing shortages by automating glucose control with high precision and safety, demonstrated in three US clinical trials with 97% glucose control and zero hypoglycemia incidents. The company is CE marked for commercial use in the EU and EEA and holds FDA Breakthrough Device designation in the US.
Admetsys
Admetsys develops a clinical robotics system for critical care and surgery that automates blood analysis and metabolic control. Their flagship product, PrecisionOne™, uses AI to model patient metabolism in real time and autonomously regulate glucose by infusing insulin and dextrose therapy without clinician intervention. The Intravenous Laboratory™ provides continuous, real-time blood diagnostics with a cartridge-based design measuring multiple analytes including glucose and lactate, enabling early sepsis detection and improved glucose control. The system improves clinical outcomes by reducing mortality, shortening ICU stays, and lowering costs. It addresses critical care challenges such as frequent blood draws and nursing shortages by automating glucose control with high precision and safety, demonstrated in three US clinical trials with 97% glucose control and zero hypoglycemia incidents. The company is CE marked for commercial use in the EU and EEA and holds FDA Breakthrough Device designation in the US.